BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15924334)

  • 21. Identification of oxazolidinediones and thiazolidinediones as potent 17β-hydroxysteroid dehydrogenase type 3 inhibitors.
    Harada K; Kubo H; Tanaka A; Nishioka K
    Bioorg Med Chem Lett; 2012 Jan; 22(1):504-7. PubMed ID: 22137341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androsterone 3alpha-ether-3beta-substituted and androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship.
    Tchédam Ngatcha B; Luu-The V; Labrie F; Poirier D
    J Med Chem; 2005 Aug; 48(16):5257-68. PubMed ID: 16078844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Substituted Aryl Benzylamines as Potent and Selective Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 3.
    Vicker N; Bailey HV; Day JM; Mahon MF; Smith A; Tutill HJ; Purohit A; Potter BVL
    Molecules; 2021 Nov; 26(23):. PubMed ID: 34885749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The (+)- and (-)-gossypols potently inhibit both 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase 3 in human and rat testes.
    Hu GX; Zhou HY; Li XW; Chen BB; Xiao YC; Lian QQ; Liang G; Kim HH; Zheng ZQ; Hardy DO; Ge RS
    J Steroid Biochem Mol Biol; 2009 May; 115(1-2):14-9. PubMed ID: 19429456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.
    Schuster D; Nashev LG; Kirchmair J; Laggner C; Wolber G; Langer T; Odermatt A
    J Med Chem; 2008 Jul; 51(14):4188-99. PubMed ID: 18533708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of type 2 17beta-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: structure-activity relationships.
    Bydal P; Auger S; Poirier D
    Steroids; 2004 May; 69(5):325-42. PubMed ID: 15219411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 17beta-hydroxysteroid dehydrogenase-3 deficiency: a rare endocrine cause of male-to-female sex reversal.
    Bertelloni S; Maggio MC; Federico G; Baroncelli G; Hiort O
    Gynecol Endocrinol; 2006 Sep; 22(9):488-94. PubMed ID: 17071532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Caenorhabditis elegans LET-767 is able to metabolize androgens and estrogens and likely shares common ancestor with human types 3 and 12 17beta-hydroxysteroid dehydrogenases.
    Desnoyers S; Blanchard PG; St-Laurent JF; Gagnon SN; Baillie DL; Luu-The V
    J Endocrinol; 2007 Nov; 195(2):271-9. PubMed ID: 17951538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
    Bey E; Marchais-Oberwinkler S; Kruchten P; Frotscher M; Werth R; Oster A; Algül O; Neugebauer A; Hartmann RW
    Bioorg Med Chem; 2008 Jun; 16(12):6423-35. PubMed ID: 18514529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor.
    Watanabe K; Kakefuda A; Yasuda M; Enjo K; Kikuchi A; Furutani T; Naritomi Y; Otsuka Y; Okada M; Ohta M
    Bioorg Med Chem; 2013 Sep; 21(17):5261-70. PubMed ID: 23845281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of chemically diverse, novel inhibitors of 17β-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening.
    Schuster D; Kowalik D; Kirchmair J; Laggner C; Markt P; Aebischer-Gumy C; Ströhle F; Möller G; Wolber G; Wilckens T; Langer T; Odermatt A; Adamski J
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):148-61. PubMed ID: 21300150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a biological screening system for the evaluation of highly active and selective 17beta-HSD1-inhibitors as potential therapeutic agents.
    Kruchten P; Werth R; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):154-7. PubMed ID: 18984028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis of 3-spiromorpholinone androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
    Djigoué GB; Kenmogne LC; Roy J; Poirier D
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6360-2. PubMed ID: 24144853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proliferative effect of androst-4-ene-3,17-dione and its metabolites in the androgen-sensitive LNCaP cell line.
    Laplante Y; Poirier D
    Steroids; 2008 Mar; 73(3):266-71. PubMed ID: 18082864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacophore modelling of 17beta-HSD1 enzyme based on active inhibitors and enzyme structure.
    Karkola S; Alho-Richmond S; Wahala K
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):225-8. PubMed ID: 18822344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and biological evaluation of phenyl substituted 1H-1,2,4-triazoles as non-steroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 2.
    Al-Soud YA; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    Arch Pharm (Weinheim); 2012 Aug; 345(8):610-21. PubMed ID: 22532378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reprint of "In vitro and in vivo evaluation of a 3β-androsterone derivative as inhibitor of 17β-hydroxysteroid dehydrogenase type 3".
    Roy J; Fournier MA; Maltais R; Kenmogne LC; Poirier D
    J Steroid Biochem Mol Biol; 2015 Sep; 153():170-8. PubMed ID: 26291835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitors of human and rat testes microsomal 17beta-hydroxysteroid dehydrogenase (17beta-HSD) as potential agents for prostatic cancer.
    Le Lain R; Nicholls PJ; Smith HJ; Maharlouie FH
    J Enzyme Inhib; 2001 Jan; 16(1):35-45. PubMed ID: 11496833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis.
    Day JM; Tutill HJ; Purohit A; Reed MJ
    Endocr Relat Cancer; 2008 Sep; 15(3):665-92. PubMed ID: 18541621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A- and D-Ring Structural Modifications of an Androsterone Derivative Inhibiting 17β-Hydroxysteroid Dehydrogenase Type 3: Chemical Synthesis and Structure-Activity Relationships.
    Cortés-Benítez F; Roy J; Perreault M; Maltais R; Poirier D
    J Med Chem; 2019 Aug; 62(15):7070-7088. PubMed ID: 31268309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.